Academic Journal of Medicine & Health Sciences, 2024, 5(5); doi: 10.25236/AJMHS.2024.050502.
Zhong Jiayi
Guangdong Experimental Middle School, Guangzhou, China
In this study, we synthesized and prepared nanomedicines with microenvironment responsive and optical activity targeting the high ROS, hypoxic, and acidic characteristics of the tumor microenvironment. We speculate that using MOC-68 mediated photodynamic therapy to inhibit tumor growth, combined with hydrogen sulfide loaded donor DATS, and integrating hollow mesoporous MnO2 nanoparticles to improve PDT efficiency, while achieving MRI visualization monitoring of the treatment process. We conducted some preliminary experiments, and the research results preliminarily confirmed that the hypothesis of the topic is reasonable and has potential.
Triple-negative breast cancer, Photodynamic therapy, nanodrugs, ROS
Zhong Jiayi. Nanomedicine enhanced photodynamic therapy for triple negative breast cancer. Academic Journal of Medicine & Health Sciences (2024), Vol. 5, Issue 5: 7-12. https://doi.org/10.25236/AJMHS.2024.050502.
[1] Dai X, Xiang L, Li T, Bai Z. Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. J Cancer. 2016 Jun 23; 7(10):1281-94.
[2] Asleh K, Riaz N, Nielsen TO. Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. J Exp Clin Cancer Res. 2022 Sep 1; 41(1):265.
[3] Huang Y, Zheng C, Zhang X, Cheng Z, Yang Z, Hao Y, Shen J. The Usefulness of Bayesian Network in Assessing the Risk of Triple-Negative Breast Cancer. Acad Radiol. 2020 Dec; 27(12):e282-e291.
[4] Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016 Nov; 13(11):674-690.
[5] Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022 Aug 29; 15(1):121.
[6] Geisler, S.; Lønning, P.E.; Aas, T.; Johnsen, H.; Fluge, O.; Haugen, D.F.; Lillehaug, J.R.; Akslen, L.A.; Børresen-Dale, A.L. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 2001, 61, 2505–2512.
[7] Maker, A.V.; Attia, P.; Rosenberg, S.A. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 2005, 175, 7746–7754.
[8] de Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 2023 Mar 13; 41(3):374-403.
[9] Cheung EC, Vousden KH. The role of ROS in tumour development and progression. Nat Rev Cancer. 2022 May; 22(5):280-297.
[10] Jin F, Wu Z, Hu X, Zhang J, Gao Z, Han X, Qin J, Li C, Wang Y. The PI3K/Akt/GSK-3β/ROS/eIF2B pathway promotes breast cancer growth and metastasis via suppression of NK cell cytotoxicity and tumor cell susceptibility. Cancer Biol Med. 2019 Feb; 16(1):38-54.
[11] Ren Y, Lin Y, Chen J, Jin Y. Disulfiram Chelated with Copper Promotes Apoptosis in Osteosarcoma via ROS/Mitochondria Pathway. Biol Pharm Bull. 2021; 44(10):1557-1564.
[12] Dekker Y, Le Dévédec SE, Danen EHJ, Liu Q. Crosstalk between Hypoxia and Extracellular Matrix in the Tumor Microenvironment in Breast Cancer. Genes (Basel). 2022 Sep 3; 13(9):1585.
[13] Cheng SY, Yang YC, Ting KL, Wen SY, Viswanadha VP, Huang CY, Kuo WW. Lactate dehydrogenase downregulation mediates the inhibitory effect of diallyl trisulfide on proliferation, metastasis, and invasion in triple-negative breast cancer. Environ Toxicol. 2017 Apr; 32(4):1390-1398.
[14] de Heer EC, Jalving M, Harris AL. HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer. J Clin Invest. 2020 Oct 1; 130(10):5074-5087.
[15] Yang B, Chen Y, Shi J. Tumor-Specific Chemotherapy by Nanomedicine-Enabled Differential Stress Sensitization. Angew Chem Int Ed Engl. 2020 Jun 8; 59(24):9693-9701.
[16] Ostańska E, Aebisher D, Bartusik-Aebisher D. The potential of photodynamic therapy in current breast cancer treatment methodologies. Biomed Pharmacother. 2021 May; 137:111302.
[17] Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, Korbelik M, Moan J, Mroz P, Nowis D, Piette J, Wilson BC, Golab J. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011 Jul-Aug;61(4):250-81.
[18] Korbelik M. PDT-associated host response and its role in the therapy outcome. Lasers Surg Med. 2006 Jun; 38(5):500-8.
[19] Malla R, Marni R, Chakraborty A, Kamal MA. Diallyl disulfide and diallyl trisulfide in garlic as novel therapeutic agents to overcome drug resistance in breast cancer. J Pharm Anal. 2022 Apr;12(2):221-231.
[20] Chen H, Guan X, Liu Q, Yang L, Guo J, Gao F, Qi Y, Wu X, Zhang F, Tian X. Co-assembled Nanocarriers of De Novo Thiol-Activated Hydrogen Sulfide Donors with an RGDFF Pentapeptide for Targeted Therapy of Non-Small-Cell Lung Cancer. ACS Appl Mater Interfaces. 2022 Dec 7; 14(48): 53475-53490.